Certificate of Analysis (COA) View the laboratory certificate for this product [ View COA ]

Pure Eloralintide 10mg | Selective Amylin Research Peptide

R 2,399.00
Add to WishlistCompare

Pure Eloralintide 10mg

Research Grade • 10mg Reference Strength • Third-Party Verified

Pure Eloralintide 10mg is a research-grade peptide containing eloralintide (LY3841136), an investigational long-acting selective amylin receptor agonist being studied in metabolic and obesity-related research.

Eloralintide is designed to preferentially activate the amylin 1 receptor (AMY1R), providing researchers with a distinct pathway for investigating appetite, satiety, food-intake regulation and metabolic signalling.

Research Focus

Eloralintide is currently being investigated across clinical research programmes examining:

  • Amylin receptor signalling
  • Appetite and satiety pathways
  • Food-intake regulation
  • Body-weight research
  • Metabolic research
  • Obesity-related research
  • Combination approaches involving incretin pathways
  • Cardiometabolic research

Current clinical development includes Phase 3 studies evaluating eloralintide in different obesity and overweight research populations, including studies involving type 2 diabetes, obstructive sleep apnea, osteoarthritis and combination therapy with weekly incretin-based treatment.

Key Features

• 10mg research-grade peptide
• Eloralintide / LY3841136
• Selective amylin receptor agonist
• Designed for AMY1R-focused research
• Metabolic and appetite-pathway research
• Third-party verified
• CAS 2883634-40-8
• Research purposes only

Dosage & Usage

REFERENCE RECONSTITUTION INFORMATION

Research Goal: Investigate selective amylin-receptor activation in appetite, food-intake, body-weight and metabolic models.

Evidence Status: Preclinical studies plus published Phase 1 human studies; ongoing clinical development.

Human Clinical Route: Subcutaneous injection.

Human Clinical Frequency: Once weekly in the published multiple-dose Phase 1 study.

Published Human Dose Exposure: Single-dose Phase 1 research evaluated 0.04–12 mg.

Product Strength: 10 mg vial.

Always follow sterile preparation techniques when handling research peptides.

The Pure Performance Labs profile records the published clinical-research doses and frequency without converting them into a self-administration titration schedule.

General Preparation

Published Phase 1 multiple-dose research evaluated 1.2 mg, 3 mg, 6 mg and 12 mg administered subcutaneously once weekly for 12 weeks without dose escalation.

Eloralintide (10mg) - RECONSTITUTION TABLES

Reference Handling Information

Reference information for laboratory handling of Eloralintide 10mg.

  • Subcutaneous injection once weekly in published multiple-dose Phase 1 research.

Reference Parameters (Published Clinical Research Summary (weekly subcutaneous injection))

DosageDoseReconstituted with 2mlUnitsLow2.5 mg50Medium5 mg100Higher7.5 mg2 x 75Highest Phase 1 repeated dose10 mg2 x 100For laboratory research only.

Experimental Study Period

STUDY PERIOD12 weeksADJUSTMENT NOTESWithout dose escalationRESEARCH CONTEXTInvestigate selective amylin-receptor activation in appetite, food-intake, body-weight and metabolic models.

FAQ's & Tips

What is Eloralintide?

Eloralintide, also known as LY3841136, is an investigational selective amylin receptor agonist being studied in metabolic and obesity-related research.

What does Eloralintide research focus on?

Research focuses on amylin receptor signalling, appetite, satiety, food intake, body-weight regulation and metabolic pathways.

Is Eloralintide a GLP-1?

No. Eloralintide is a selective amylin receptor agonist, rather than a GLP-1 receptor agonist. Its mechanism is centred on the amylin receptor pathway.

What is the research code for Eloralintide?

The research code is LY3841136, also written as LY-3841136.

What is the CAS number?

The CAS number listed for Eloralintide is 2883634-40-8.

What strength is this product?

This product has a 10mg reference strength.

Is Eloralintide approved?

Eloralintide remains an investigational compound undergoing clinical development and is not an approved medicine.

What research category does Eloralintide belong to?

Metabolic Research, with particular relevance to amylin receptor, appetite, satiety and body-weight research.

Research
  • Amylin receptor pharmacology

  • AMY1R signalling

  • Appetite and satiety

  • Food-intake regulation

  • Metabolic signalling

  • Body-weight research

  • Obesity research

  • Cardiometabolic research

  • Combination research with incretin-based therapies

As of 2026, eloralintide is being investigated in multiple Phase 3 clinical programmes.

Reviews